A single-center , double-blinded study was performed in 32 healthy subjects randomized 3:1 to receive a single subcutaneous administration of DX-2930 or placebo within 1 of 4 sequential , ascending dose cohorts ( n = 8 each ) : 0.1 , 0.3 , 1.0 , or 3.0 mg/kg .